Brief: Adaptimmune Therapeutics FDA Accepted For Priority Review BLA For T-Cell Therapy For Advanced Synovial Sarcoma

Adaptimmune Therapeutics

31/01/2024 23:08

Jan 31 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * ADAPTIMMUNE THERAPEUTICS: FDA ACCEPTED FOR PRIORITY REVIEW
BLA
FOR AFAMI-CEL, INVESTIGATIONAL ENGINEERED T-CELL THERAPY FOR
ADVANCED SYNOVIAL SARCOMA
    * ADAPTIMMUNE THERAPEUTICS PLC: APPLICATION HAS PDUFA TARGET
ACTION DATE OF AUGUST 4
    * ADAPTIMMUNE THERAPEUTICS: ACCEPTANCE SUPPORTED BY POSITIVE
DATA
FROM COHORT 1 OF PIVOTAL TRIAL SPEARHEAD-1, WHICH MET PRIMARY
ENDPOINT FOR EFFICACY

Source text for Eikon:  ID:n0001558370-24-000672 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))